Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE).

Overview
Research
Identity
Additional Document Info
View All

authors

Smith, Tania
Navarro-Gualito, Maria D
Cruz-Carbajal, Alejandra S
Cortes-Vazquez, Miguel A
Bekker-Méndez, Carolina
Aguirre-Alvarado, Charmina
Aguirre-Gil, Gisela
Delgado-Pastelin, Lucero
Owen, Andrew
Lowe, David
Standing, Joseph
Hoyo-Vadillo, Carlos
Escobedo, Jorge
Adom, Akosua Agyeman
Favari-Perozzi, Liliana
Gastine, Silke
Dehbi, Hakim-Moulay
Villegas-Lara, Beatriz
Mateos, Eduardo
González, Yessica Sara Pérez

publication date

January 1, 2022

published in

Trials Journal

has subject area